Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
Cancer
|
June 24, 2023
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML
Mario Tiribelli, Roberto Latagliata, Massimo Breccia, et al.
Cancer
|
June 29, 2025
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus
Valentina Giai, Tiziana Rosso, Fausto Castagnetti, et al.
Frontiers in Oncology
|
September 13, 2021
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
Giorgina Specchia, Patrizia Pregno, Massimo Breccia, et al.
Haematologica
|
March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
Blood Advances
|
January 7, 2026
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort
Enrica Antonia Martino, Annalisa Pitino, Ernesto Vigna, et al.
Hematological Oncology
|
December 29, 2025
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study
Ernesto Vigna, Enrica Antonia Martino, Annalisa Pitino, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
Cancer
|
June 24, 2023
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML
Mario Tiribelli, Roberto Latagliata, Massimo Breccia, et al.
Cancer
|
June 29, 2025
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus
Valentina Giai, Tiziana Rosso, Fausto Castagnetti, et al.
Frontiers in Oncology
|
September 13, 2021
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
Giorgina Specchia, Patrizia Pregno, Massimo Breccia, et al.
Haematologica
|
March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
Blood Advances
|
January 7, 2026
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort
Enrica Antonia Martino, Annalisa Pitino, Ernesto Vigna, et al.
Hematological Oncology
|
December 29, 2025
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study
Ernesto Vigna, Enrica Antonia Martino, Annalisa Pitino, et al.
Page
of 3